Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QVM149 morning versus evening dosing crossover study in asthma
NL-OMON44320Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Jun 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of indacaterol acetate + glycopyrronium bromide + mometasone furoate in asthma (3 arms), sponsored by Novartis. Started Jun 2017; status: active, not recruiting.
02
Drugs
indacaterol acetate + glycopyrronium bromide + mometasone furoate
03
Conditions
asthma
Beyond the preview
Go deeper on NL-OMON44320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44320.